240 related articles for article (PubMed ID: 21185805)
1. Harmine is an ATP-competitive inhibitor for dual-specificity tyrosine phosphorylation-regulated kinase 1A (Dyrk1A).
Adayev T; Wegiel J; Hwang YW
Arch Biochem Biophys; 2011 Mar; 507(2):212-8. PubMed ID: 21185805
[TBL] [Abstract][Full Text] [Related]
2. Harmine specifically inhibits protein kinase DYRK1A and interferes with neurite formation.
Göckler N; Jofre G; Papadopoulos C; Soppa U; Tejedor FJ; Becker W
FEBS J; 2009 Nov; 276(21):6324-37. PubMed ID: 19796173
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and biological evaluation of harmine derivatives as potent GSK-3β/DYRK1A dual inhibitors for the treatment of Alzheimer's disease.
Liu W; Liu X; Tian L; Gao Y; Liu W; Chen H; Jiang X; Xu Z; Ding H; Zhao Q
Eur J Med Chem; 2021 Oct; 222():113554. PubMed ID: 34098466
[TBL] [Abstract][Full Text] [Related]
4. How to Separate Kinase Inhibition from Undesired Monoamine Oxidase A Inhibition-The Development of the DYRK1A Inhibitor AnnH75 from the Alkaloid Harmine.
Wurzlbauer A; Rüben K; Gürdal E; Chaikuad A; Knapp S; Sippl W; Becker W; Bracher F
Molecules; 2020 Dec; 25(24):. PubMed ID: 33339338
[TBL] [Abstract][Full Text] [Related]
5. DYRK1A phosphorylates caspase 9 at an inhibitory site and is potently inhibited in human cells by harmine.
Seifert A; Allan LA; Clarke PR
FEBS J; 2008 Dec; 275(24):6268-80. PubMed ID: 19016842
[TBL] [Abstract][Full Text] [Related]
6. Rational Design and Identification of Harmine-Inspired, N-Heterocyclic DYRK1A Inhibitors Employing a Functional Genomic In Vivo Drosophila Model System.
Huizar FJ; Hill HM; Bacher EP; Eckert KE; Gulotty EM; Rodriguez KX; Tucker ZD; Banerjee M; Liu H; Wiest O; Zartman J; Ashfeld BL
ChemMedChem; 2022 Feb; 17(4):e202100512. PubMed ID: 34994084
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and Biological Validation of a Harmine-Based, Central Nervous System (CNS)-Avoidant, Selective, Human β-Cell Regenerative Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase A (DYRK1A) Inhibitor.
Kumar K; Wang P; Wilson J; Zlatanic V; Berrouet C; Khamrui S; Secor C; Swartz EA; Lazarus M; Sanchez R; Stewart AF; Garcia-Ocana A; DeVita RJ
J Med Chem; 2020 Mar; 63(6):2986-3003. PubMed ID: 32003560
[TBL] [Abstract][Full Text] [Related]
8. β-carboline compounds, including harmine, inhibit DYRK1A and tau phosphorylation at multiple Alzheimer's disease-related sites.
Frost D; Meechoovet B; Wang T; Gately S; Giorgetti M; Shcherbakova I; Dunckley T
PLoS One; 2011 May; 6(5):e19264. PubMed ID: 21573099
[TBL] [Abstract][Full Text] [Related]
9. Kinetic properties of a MNB/DYRK1A mutant suitable for the elucidation of biochemical pathways.
Adayev T; Chen-Hwang MC; Murakami N; Wegiel J; Hwang YW
Biochemistry; 2006 Oct; 45(39):12011-9. PubMed ID: 17002300
[TBL] [Abstract][Full Text] [Related]
10. Exploiting the repertoire of CK2 inhibitors to target DYRK and PIM kinases.
Cozza G; Sarno S; Ruzzene M; Girardi C; Orzeszko A; Kazimierczuk Z; Zagotto G; Bonaiuto E; Di Paolo ML; Pinna LA
Biochim Biophys Acta; 2013 Jul; 1834(7):1402-9. PubMed ID: 23360763
[TBL] [Abstract][Full Text] [Related]
11. Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.
Nguyen TL; Fruit C; Hérault Y; Meijer L; Besson T
Expert Opin Ther Pat; 2017 Nov; 27(11):1183-1199. PubMed ID: 28766366
[TBL] [Abstract][Full Text] [Related]
12. Structure-Based Design and Synthesis of Harmine Derivatives with Different Selectivity Profiles in Kinase versus Monoamine Oxidase Inhibition.
Bálint B; Wéber C; Cruzalegui F; Burbridge M; Kotschy A
ChemMedChem; 2017 Jun; 12(12):932-939. PubMed ID: 28264138
[TBL] [Abstract][Full Text] [Related]
13. Pharmacologic and genetic approaches define human pancreatic β cell mitogenic targets of DYRK1A inhibitors.
Ackeifi C; Swartz E; Kumar K; Liu H; Chalada S; Karakose E; Scott DK; Garcia-Ocaña A; Sanchez R; DeVita RJ; Stewart AF; Wang P
JCI Insight; 2020 Jan; 5(1):. PubMed ID: 31821176
[TBL] [Abstract][Full Text] [Related]
14. The small molecule harmine regulates NFATc1 and Id2 expression in osteoclast progenitor cells.
Egusa H; Doi M; Saeki M; Fukuyasu S; Akashi Y; Yokota Y; Yatani H; Kamisaki Y
Bone; 2011 Aug; 49(2):264-74. PubMed ID: 21504804
[TBL] [Abstract][Full Text] [Related]
15. Activation, regulation, and inhibition of DYRK1A.
Becker W; Sippl W
FEBS J; 2011 Jan; 278(2):246-56. PubMed ID: 21126318
[TBL] [Abstract][Full Text] [Related]
16. Identification of harmine and β-carboline analogs from a high-throughput screen of an approved drug collection; profiling as differential inhibitors of DYRK1A and monoamine oxidase A and for in vitro and in vivo anti-cancer studies.
Tarpley M; Oladapo HO; Strepay D; Caligan TB; Chdid L; Shehata H; Roques JR; Thomas R; Laudeman CP; Onyenwoke RU; Darr DB; Williams KP
Eur J Pharm Sci; 2021 Jul; 162():105821. PubMed ID: 33781856
[TBL] [Abstract][Full Text] [Related]
17. Neprilysin Is Suppressed by Dual-Specificity Tyrosine-Phosphorylation Regulated Kinase 1A (DYRK1A) in Down-Syndrome-Derived Fibroblasts.
Kawakubo T; Mori R; Shirotani K; Iwata N; Asai M
Biol Pharm Bull; 2017; 40(3):327-333. PubMed ID: 28250274
[TBL] [Abstract][Full Text] [Related]
18. Generation of highly potent DYRK1A-dependent inducers of human β-Cell replication via Multi-Dimensional compound optimization.
Allegretti PA; Horton TM; Abdolazimi Y; Moeller HP; Yeh B; Caffet M; Michel G; Smith M; Annes JP
Bioorg Med Chem; 2020 Jan; 28(1):115193. PubMed ID: 31757680
[TBL] [Abstract][Full Text] [Related]
19. A natural compound harmine decreases melanin synthesis through regulation of the DYRK1A/NFATC3 pathway.
Park CH; Kim G; Lee Y; Kim H; Song MJ; Lee DH; Chung JH
J Dermatol Sci; 2021 Jul; 103(1):16-24. PubMed ID: 34030962
[TBL] [Abstract][Full Text] [Related]
20. The kinase DYRK1A reciprocally regulates the differentiation of Th17 and regulatory T cells.
Khor B; Gagnon JD; Goel G; Roche MI; Conway KL; Tran K; Aldrich LN; Sundberg TB; Paterson AM; Mordecai S; Dombkowski D; Schirmer M; Tan PH; Bhan AK; Roychoudhuri R; Restifo NP; O'Shea JJ; Medoff BD; Shamji AF; Schreiber SL; Sharpe AH; Shaw SY; Xavier RJ
Elife; 2015 May; 4():. PubMed ID: 25998054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]